Gastric cancer is one of the major malignancies worldwide, with high incidence and mortality rates. Early detection is critical, as patient prognosis significantly depends on the stage at diagnosis. However, due to the lack of symptoms in early stages, a substantial number of patients are still diagnosed at advanced stages.
At NEORNAT, we are developing a panel-based in vitro diagnostic kit for early detection of gastric cancer, utilizing highly specific multiple biomarkers. This platform is designed to enable early risk assessment through a simple blood-based test, offering a more accessible and efficient approach to gastric cancer screening.